StockData
Precigen, Inc. logo

Precigen, Inc. (PGEN) company profile

PGENNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 2/30
$4.29−0.01 (-0.23%)

Close on Nov 17, 2026Market cap $1.54BP/E –Yield –

About Precigen

Pharmaceutical Preparations, SIC 2834

Precigen is a commercial-stage biopharmaceutical company focused on precision medicines for immuno-oncology, autoimmune disorders, and infectious diseases. Utilizing platforms such as AdenoVerse, UltraVector, and UltraCAR-T, the company engineers gene programs and therapies targeting intractable conditions. Its first commercial product is Papzimeos, an adenoviral vector-based immunotherapy approved for treating adult recurrent respiratory papillomatosis. Precigen also maintains an investigational pipeline that includes PRGN-2009 for human papillomavirus-associated malignancies and PRGN-3006 for acute myeloid leukemia. Its offerings serve adult patients, healthcare providers, and integrated delivery networks managing rare diseases and oncology indications.

The company operates internal current good manufacturing practices facilities in Germantown, Maryland, to support drug substance manufacturing and commercial supply. Precigen distributes its approved therapy nationwide across the United States through hospital systems, community clinics, and integrated delivery networks. Additionally, the company seeks international expansion, having submitted a marketing application for European review. Precigen conducts clinical trials at partner institutions across the country and collaborates with entities including the National Cancer Institute.

Summary of the business section of Precigen's latest annual report, written by StockData.

Company profile

Company

Legal name
Precigen, Inc.
Founded
1998
Headquarters
Germantown, MD
Address
20374 Seneca Meadows Parkway 20876
Phone
(301) 556-9900
Employees
20, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Virginia
Fiscal year ends
December 31
Auditor
Deloitte & Touche LLP, Baltimore, Maryland

Stock & identifiers

Ticker
PGEN
Former tickers
XON until Feb 4, 2020
Exchange
Nasdaq
IPO date
Aug 8, 2013
Shares outstanding
358M, Jul 31, 2026
Public float
$219.40M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1356090
CUSIP
46122T102
ISIN
US46122T1025
FIGI
BBG000QL8VH9
Share class FIGI
BBG001SSB3T5
LEI
549300XCWNQU35K64G19
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Harry Thomasian Jr.Chief Financial Officer311,911
Donald P. LehrChief Legal Officer758,181
Phil TennantChief Commercial Officer221,158
Helen SabzevariPresident and CEO3,789,705
Rutul R. ShahChief Operating Officer468,865
Jeffrey B. KindlerDirector17,100
Nancy H. AgeeDirector309,187
Randal J. KirkDirector116,301,090
Vinita D. GuptaDirector669,027
Fred HassanDirector1,243,239
Cesar L. AlvarezDirector782,909
Steven FrankDirector1,226,391
James S. TurleyDirector685,417

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$5.35M$18.57M$1.43M$41$125
FY2024$5.43M$4.61M$1.31M$20$114
FY2023$3.72M$3.73M$1.03M$24$115
FY2022$3.50M-$1.09M$892.36K$28$111
FY2021$2.52M-$16.11M$611.02K$68$125
FY2020$20.41M$41.48M$1.17M$186$126

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Helen Sabzevari
Chief Executive Officer
$1.00M$2.22M$1.07M$1.05M$20.13K$5.35M-1%
Harry Thomasian Jr.
Chief Financial Officer
$488.00K$464.97K$374.22K$131.76K$35.76K$1.49M+7%
Donald P. Lehr
Chief Legal Officer
$575.00K$408.75K$267.30K$132.25K$46.90K$1.43M+6%
Rutul Shah
Chief Operating Officer
$485.00K$499.90K$384.91K$145.50K$45.60K$1.56M+11%
Phil Tennant
Chief Commercial Officer
$510.00K$271.10K$267.30K$137.70K$43.85K$1.23M+137%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Aug 8, 2013
Offer price
$16.00
Securities offered
9,999,999
Gross proceeds
$160.00M
Exchange
NYSE
First trading day
Aug 8, 2013
First-day close
$24.73+54.6%
Lock-up ends (est.)
Feb 4, 2014

“Per share Total Initial public offering price $ 16.00 $ 159,999,984 Underwriting discount s and commissions(1) $ 1.12 $ 11,199,999 Proceeds to us, before expenses $ 14.88 $ 148,799,985 (1) We refer you to “Underwriting” beginning on page 166 for additional information regarding total underwriting compensation.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, Exemplar had 20 employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?